Moderna

Ebola outbreak
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Moderna #Outbreak

Phase I trial “a major step forward” against Ebola outbreak

Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV).  “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More

#Editor's Choice #News #Trending News

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News

Melanoma or skin cancer
#Clinical trial #Melanoma #Merck #Moderna

Combination therapy could slash melanoma mortality risk 

Merck and Moderna have announced encouraging five-year data for a therapy treating patients with high-risk melanoma.  The Phase IIb trial of intismeran autogene, an investigational mRNA-based individualised neoantigen therapy (INT), reduced the risk of high-risk melanoma recurrence or death by 49% when combined with Keytruda (pembrolizumab).  The combination… Read More

#News

mRNA
#CEPI #Immunology / Virology & Vaccines #Influenza #Moderna #mRNA #Pandemic prevention #Pandemic response

$54.3m CEPI investment boosts Moderna’s H5 influenza vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.   The organisation says the funding marks a significant step… Read More

#Business & Investment #News

#Immunology / Virology & Vaccines #Moderna #mRNA-based vaccines #Streptococcus #University of Queensland

Researchers step closer to a universal Strep-A mRNA vaccine

A team of microbiologists and immunologists has completed the first steps towards developing a universal vaccine against Group A Streptococcus (Strep-A).  The University of Queensland-led research in partnership with Moderna and published in Nature Communications has shown Strep-A can be successfully targeted using… Read More

#Editor's Choice #News

Liver cancer
#Moderna #mRNA #Oncology #Phase I trial #Solid tumours

Pan-tumour antigen therapy candidate enters the clinic

The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours.  The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik. Read More

#Cancer Research #News

#Artificial intelligence (AI) #Benchling #Collaboration #Moderna

Moderna and Benchling collaborate on AI-driven research

Moderna and Benchling have extended their collaboration into a broader rollout across the company’s research organisation.   The expansion will bring hundreds of Moderna’s scientists onto a unified, AI-ready research and development digital platform designed to accelerate discovery and innovation.  “Moderna was built on the belief… Read More

#Business & Investment #News

Close up of vaccine syringe
#Covid-19 #Covid-19 vaccine #Flu vaccine #Immunology / Virology & Vaccines #Influenza #Moderna

Combination vaccine better than separate flu and Covid-19 jabs

In clinical trials, Moderna’s combination vaccine elicited higher immune responses against influenza (flu) virus and SARS-CoV-2 than licensed flu and Covid-19 vaccines in adults 50 years and older. The Phase III trial investigated mRNA-1083, an investigational combination vaccine against influenza and Covid-19. mRNA-1083 comprises… Read More

#News #Trending News

#FDA #Immunology / Virology & Vaccines #Moderna #mRNA #mRNA-based vaccines #Respiratory syncytial virus

US approves first mRNA vaccine since Covid-19

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks… Read More

#News #Regulatory

Vaccine vial and syringe
#Cancer vaccine #Imperial College London #Moderna #mRNA-based vaccines #Oncology #Phase I trial

First UK patients receive experimental mRNA therapy for cancer

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The Mobilize trial is run in partnership between Imperial College London and… Read More

#Cancer Research #News #Trending News

mRNA
#King's College London #Liver disease #Moderna #Mouse models #mRNA #Rare disease #University College London

Study reveals therapeutic potential of mRNA in rare diseases

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. The team, led by University College London (UCL), King’s College London and Moderna scientists, found that mRNA could be… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Big pharma #BioNTech #Biopharmaceuticals #Comirnaty #Covid-19 #Drug discovery #Healthcare #Moderna #mRNA #Pfizer

New podcast on drug discovery trends

This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and… Read More

#News

Cancer cells
#Bispecific therapeutics #Cancer research #Collaboration #Drug development #Immatics #Moderna #mRNA

Multi-platform collab to develop innovative oncology therapeutics 

Moderna and Immatics have announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high, unmet medical need.   This broad multi-platform collaboration will leverage the scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s… Read More

#Cancer Research #News

Preparing Covid-19 vaccine for injection
#BioNTech #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Moderna #Novavax #Pfizer #Vaccines

New Covid-19 vaccines ready to slow spread of EG.5

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated… Read More

#News #Trending News